Leo Pallanck

Professor of Genome Sciences

phone: (206) 616-5997 | fax: (206) 543-0754
Foege S-443E, Box 355065
pallanck [ a t ] u.washington.edu
website

Research:

Neurodegenerative disorders constitute a major challenge of modern medicine. Although these disorders are common and often highly debilitating, the mechanisms responsible for their pathologies are poorly understood, and there are currently no effective preventative therapies. My laboratory has used two complementary approaches to address these matters. One approach has been to use classical genetic approaches in the fruit fly Drosophila melanogaster to study the normal development and function of the nervous system. Specifically, we have been studying the molecular mechanisms by which neurons form synapses and communicate with one another through the regulated release of chemical neurotransmitters. The premise of this work is that knowledge of the normal development and function of the nervous system will be a prerequisite to a complete understanding of the mechanisms by which neurons become dysfunctional and die in disease states. In more recent work, that now represents the major focus of my laboratory, we have been using genetic, genomic, and proteomic methods in Drosophila to explore the biological functions of genes implicated in heritable forms of several neurodegenerative diseases. Specifically, we have been studying genes involved in Parkinson’s disease (PD) and the lipid storage pediatric neurodegerative disorder, Niemann Pick Type C disease (NPCD). The long-term goals of this work are to define the genetic pathways responsible for pathology in these disorders. Given the extensive evolutionary conservation of genetic pathways in eukaryotes, we anticipate that knowledge obtained in these studies involving Drosophila will have broad biological and medical significance.

Selected Publications:

L. Pallanck & J.T. Greenamyre (2006) PINK1, parkin and the brain. Nature, 441, 1058.

A. Whitworth, P. Wes and L. Pallanck (2006) Drosophila models pioneer a new approach to drug discovery for Parkinson’s disease. Drug Discov Today. 11, 119-126.

M. Fluegel, T. Parker, L. Pallanck (2006) Mutations of a Drosophila NPC1 gene confer sterol and ecdysone metabolic defects. Genetics , 172, 185-196.

M. Meulener, A. Whitworth, C. A. Gold, P. Rizzu, P. Heutink, P. Wes, L. Pallanck and N. M. Bonini. (2005) Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson’s disease. Curr Biol15, 1572-1577.

A. Whitworth, D. Thompson, H. Benes, P. Wes and L. Pallanck (2005) Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson’s disease. Proc. Natl. Acad. Sci. USA. 1 02 , 8024-8029 .

J. Greene, A. Whitworth, L. Andrews, T. Parker and L. Pallanck. (2005) Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum Mol Genet14, 799-811.

M. Babcock, S. Stowers, J. Leither C. Goodman and L. Pallanck. (2003) A genetic screen for synaptic transmission mutants mapping to the right arm of chromosome 3 in Drosophila. Genetics, 165, 171-183.

additional publication listings available via PubMed